Gentamicin containing collagen implants and groin wound infections in vascular surgery: a prospective randomized controlled multicenter trial. Eur J Vasc Endovasc Surg 2020; 59: 635-641
Published: 15th June 2020
Authors: Wubbeke LF, Telgenkamp B, van Boxtel T, Bolt LJJ, Houthoofd S, Vriens PW et al.
This multicenter study included 288 patients undergoing surgery with a groin incision. Use of a gentamicin implant during wound closure did not reduce surgical site infection (seven versus twelve per cent, P=0.17). Subgroup analysis revealed a benefit in hospitals with high groin infection rates.Pubmed Link
You may also be interested in
Prospective, randomized, phase II, non-inferiority study to evaluate the safety and efficacy of topical thrombin (Human) Grifols as adjunct to hemostasis during vascular, hepatic, soft tissue, and spinal open surgery. J Am Coll Surg 2019: 229: 497–507
Authors: Minkowitz H, Navarro-Puerto J, Lakshman S, Singla S, Cousar C, Kim R et al.
Inguinal vascular surgical wound protection by incisional negative pressure wound therapy. A randomized controlled trial—INVIPS Trial. Ann Surg 2020; 271: 48-53
Authors: Hasselmann J, Björk J, Svensson-Björk R, Acosta S
Meta-analysis and trial sequential analysis of prophylactic negative pressure therapy for groin wounds in vascular surgery. J Vasc Surg 2019; 70: 1700–1710
Authors: Antoniou GA, Onwuka CC, Antoniou SA, Russell D
A prospective, single-blind, randomized, phase III study to evaluate the safety and efficacy of fibrin sealant Grifols as an adjunct to hemostasis compared with manual compression in vascular surgery. J Vasc Surg 2019; 70: 1642-1651
Authors: Nenezić D, Ayguasanosa J, Menyhei G, Tamas H, Mátyás L, Muluk S et al.
A randomized clinical trial evaluating negative pressure therapy to decrease vascular groin incision complications. J Vasc Surg 2018; 68: 1744-1752.
Authors: Kwon J, Staley C, McCullough M, Goss S, Arosemena M, Abai B et al.
Management of extremity fasciotomy sites prospective randomized evaluation of two techniques. Am J Surg 2018; 216: 736–739.
Authors: Johnson LS, Chaar M, Ball CG, Perez S, Nicholas JM, Wyrzykowski AD et al.
Closed incision negative pressure therapy reduces surgical site infections in vascular surgery: a prospective randomised trial (AIMS Trial). Eur J Vasc Endovasc Surg 2018; 56: 442-448.
Authors: Gombert A, Babilon M, Barbati ME, Keszei A, von Trotha KT, Jalaie H et al.
Randomized clinical trial of negative pressure wound therapy for high-risk groin wounds in lower extremity revascularization . J Vasc Surg 2017; 66: 1814-1819.
Authors: Lee K, Murphy PB, Ingves MV, Duncan A, DeRose G, Dubois L et al.
Randomized trial of a dry-powder, fibrin sealant in vascular procedures. J Vasc Surg 2015; 62: 1288–1295.
Authors: Gupta NY, Chetter I, Hayes P, O-Yurvati AH, Moneta G, Shenov S et al.
Prospective randomized double-blinded trial comparing 2 anti-MRSA agents with supplemental coverage of cefazolin before lower extremity revascularization. Ann Surg 2015; 262: 495–501.
Authors: Stone P, AbuRahma, AF, Campbell JR, Hass S, Mousa AY et al.
A prospective randomized study of heparin-bonded graft (Propaten) versus standard graft in prosthetic arteriovenous access. J Vasc Surg 2015; 62: 115–122.
Authors: Shemesh D, Goldin I, Hijazi J, Zaghal I, Berelowitz D, Verstandig A et al. et al.
Randomized controlled trial comparing the safety and efficacy between the FUSION BIOLINE heparin-coated vascular graft and the standard expanded polytetrafluoroethylene graft for femoropopliteal bypass. J Vasc Surg 2015; 61: 703–712.
Authors: Lumsden AB, Morrissey NJ, Staffa R, Lindner J, Janousek L, Treska V et al.on behalf of the Comparison of Safety and Primary Patency Between the FUSION BIOLINE Heparin-Coated Vascular Graft and EXXCEL Soft ePTFE (FINEST) Trial Co-investigators et al.